Amgen (NASDAQ:AMGN) Shares Unloaded Rep. David Taylor

Representative David Taylor (Republican-Ohio) recently sold shares of Amgen Inc. (NASDAQ:AMGN). In a filing disclosed on September 05th, the Representative disclosed that they had sold between $1,001 and $15,000 in Amgen stock on August 26th. The trade occurred in the Representative’s “DAVID TAYLOR TRUST > SCHWAB JOINT BROKERAGE #1 (HOME GROWN)” account.

Representative David Taylor also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Vertex Pharmaceuticals (NASDAQ:VRTX) on 8/26/2026.
• Sold $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 8/26/2026.
• Purchased $1,001 – $15,000 in shares of Fifth Third Bancorp (NASDAQ:FITB) on 8/26/2026.
• Purchased $1,001 – $15,000 in shares of Broadcom (NASDAQ:AVGO) on 8/26/2026.
• Purchased $1,001 – $15,000 in shares of American Electric Power (NASDAQ:AEP) on 8/26/2026.
• Purchased $1,001 – $15,000 in shares of Installed Building Products (NYSE:IBP) on 8/14/2026.
• Purchased $1,001 – $15,000 in shares of Procter & Gamble (NYSE:PG) on 8/11/2026.
• Purchased $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOGL) on 8/11/2026.
• Sold $15,001 – $50,000 in shares of Microsoft (NASDAQ:MSFT) on 8/11/2026.
• Purchased $1,001 – $15,000 in shares of Broadcom (NASDAQ:AVGO) on 7/24/2026.

Amgen Stock Down 9.2%

AMGN stock traded down $40.22 during trading on Tuesday, hitting $397.01. 1,635,283 shares of the stock traded hands, compared to its average volume of 2,681,302. The stock has a market cap of $214.63 billion, a price-to-earnings ratio of 24.72, a price-to-earnings-growth ratio of 3.15 and a beta of 0.43. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13. Amgen Inc. has a 1 year low of $269.77 and a 1 year high of $447.03. The firm’s 50 day moving average is $398.92 and its two-hundred day moving average is $367.59.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.62 by $0.67. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The business had revenue of $10.05 billion during the quarter, compared to analysts’ expectations of $9.43 billion. During the same period in the previous year, the company earned $6.02 earnings per share. The business’s revenue for the quarter was up 9.5% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, sell-side analysts anticipate that Amgen Inc. will post 22.97 EPS for the current year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Investors of record on Friday, August 21st will be given a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend is Friday, August 21st. Amgen’s dividend payout ratio is 62.65%.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen reported that its Phase 3 DeLLphi-305 trial met its primary endpoint, showing a statistically significant and clinically meaningful overall-survival benefit for IMDELLTRA (tarlatamab) combined with AstraZeneca’s Imfinzi versus Imfinzi alone in first-line extensive-stage small-cell lung cancer. The study also met progression-free-survival and objective-response-rate endpoints, strengthening the commercial outlook for IMDELLTRA and Amgen’s oncology pipeline. Amgen DeLLphi-305 study results
• Neutral Sentiment: Cantor Fitzgerald reaffirmed its neutral rating and assigned a $400 price target, indicating limited near-term upside from the referenced price level. BMO Capital Markets also downgraded Amgen to Market Perform from Outperform, citing a more balanced risk-reward profile and limited immediate upside. BMO Amgen downgrade
• Negative Sentiment: Novartis’ Phase 3 pelacarsen trial failed to reduce cardiovascular events despite lowering Lp(a), raising doubts about whether lowering the biomarker is sufficient to prevent heart attacks and strokes. The result increased perceived risk for Amgen’s experimental Lp(a) drug olpasiran, including its large Phase 3 cardiovascular-outcomes program, and triggered concerns about a potentially important future growth opportunity. Novartis pelacarsen trial setback
• Negative Sentiment: Amgen is also being affected by broad risk-off trading as crude oil approaches $100 amid Iran-related tensions, while investors await U.S. inflation data. The market backdrop is adding pressure to large-cap healthcare stocks and amplifying the reaction to the Lp(a) pipeline concerns. Market selloff and rising oil prices

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on AMGN shares. Weiss Ratings raised Amgen from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday, August 6th. Canaccord Genuity Group boosted their price target on Amgen from $366.00 to $384.00 and gave the stock a “hold” rating in a research note on Wednesday, August 5th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $400.00 price target on shares of Amgen in a report on Tuesday. Morgan Stanley reaffirmed an “overweight” rating and set a $362.00 price objective on shares of Amgen in a research report on Wednesday, August 19th. Finally, Wells Fargo & Company lifted their price objective on Amgen from $400.00 to $435.00 and gave the stock an “equal weight” rating in a report on Friday. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, fourteen have assigned a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat, Amgen currently has a consensus rating of “Hold” and a consensus price target of $381.68.

Institutional Investors Weigh In On Amgen

A number of large investors have recently added to or reduced their stakes in AMGN. Dogwood Wealth Management LLC grew its holdings in shares of Amgen by 275.0% in the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock worth $25,000 after acquiring an additional 55 shares during the period. Anfield Capital Management LLC lifted its holdings in Amgen by 1,000.0% in the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 70 shares during the period. Tower View Wealth Management LLC lifted its holdings in Amgen by 331.6% in the first quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 63 shares during the period. Manning & Napier Advisors LLC boosted its position in Amgen by 49.2% in the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock worth $32,000 after purchasing an additional 32 shares during the last quarter. Finally, Evergreen Advisors LLC purchased a new position in Amgen in the first quarter worth about $37,000. Institutional investors own 76.50% of the company’s stock.

Insider Transactions at Amgen

In related news, SVP Nancy A. Grygiel sold 2,970 shares of the firm’s stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total value of $1,194,415.20. Following the transaction, the senior vice president owned 7,340 shares of the company’s stock, valued at approximately $2,951,854.40. This trade represents a 28.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Rachna Khosla sold 1,252 shares of the business’s stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $416.43, for a total transaction of $521,370.36. Following the sale, the senior vice president owned 6,404 shares of the company’s stock, valued at $2,666,817.72. This trade represents a 16.35% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 6,222 shares of company stock valued at $2,540,926. Corporate insiders own 0.85% of the company’s stock.

About Representative Taylor

David Taylor (Republican Party) is a member of the U.S. House, representing Ohio’s 2nd Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Taylor (Republican Party) ran for election to the U.S. House to represent Ohio’s 2nd Congressional District. He won in the general election on November 5, 2024.

David Taylor graduated from Amelia High School. Taylor earned degrees from Miami University (Ohio) and the University of Dayton School of Law. Taylor’s career experience includes working as an attorney and as a businessman at Sardinia Ready Mix, Inc.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.